Open AccessThis article is
- freely available
Targeted Therapies in Epithelial Ovarian Cancer
Christie Hospital NHS Foundation Trust / Wilmslow Road, Manchester, M20 4BX, United Kingdom
* Author to whom correspondence should be addressed.
Received: 18 January 2010; in revised form: 2 February 2010 / Accepted: 11 February 2010 / Published: 23 February 2010
Abstract: Molecularly targeted therapy is relatively new to ovarian cancer despite the unquestionable success with these agents in other solid tumours such as breast and colorectal cancer. Advanced ovarian cancer is chemosensitive and patients can survive several years on treatment. However chemotherapy diminishes in efficacy over time whilst toxicities persist. Newer biological agents that target explicit molecular pathways and lack specific chemotherapy toxicities such as myelosuppression offer the advantage of long-term therapy with a manageable toxicity profile enabling patients to enjoy a good quality of life. In this review we appraise the emerging data on novel targeted therapies in ovarian cancer. We discuss the role of these compounds in the front-line treatment of ovarian cancer and in relapsed disease; and describe how the development of predictive clinical, molecular and imaging biomarkers will define the role of biological agents in the treatment of ovarian cancer.
Keywords: ovarian cancer; targeted therapy
Citations to this Article
Cite This Article
MDPI and ACS Style
Dean, E.; El-Helw, L.; Hasan, J. Targeted Therapies in Epithelial Ovarian Cancer. Cancers 2010, 2, 88-113.
Dean E, El-Helw L, Hasan J. Targeted Therapies in Epithelial Ovarian Cancer. Cancers. 2010; 2(1):88-113.
Dean, Emma; El-Helw, Loaie; Hasan, Jurjees. 2010. "Targeted Therapies in Epithelial Ovarian Cancer." Cancers 2, no. 1: 88-113.